The only customers I can possibly see at this point are backyard academic researchers which will NOT bring the returns to holders being voiced.
Other than that, the other option will be the pre-clinical and potentially clinical development route that will take time, money and little return in the short to mid term, meaning the next 2-5 years.
Company has already pointed out that this will be happening.
About to explode, page-3
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
